High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Eli Lilly and Company (NYSE:LLY) is one of the top long-term stocks to buy. On May 25, Eli Lilly and Company (NYSE:LLY) delivered positive Phase 1b Heart-2 study results for VERVE-102, an investigational base-editing therapy designed to deactivate the PCSK9 gene in the liver. The trial results show that VERVE-102 successfully reduced PCSK9 by up […]
Eli Lilly is working on a new GLP-1 drug, and early results suggest it could be a big winner.
CVS Caremark has granted preferred formulary status to both Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo. This decision reverses Wegovy's prior commercial advantage within CVS Caremark's GLP-1 obesity drug coverage. The change affects access and competitive positioning for GLP-1 obesity therapies in CVS Caremark's network. Novo Nordisk, listed as CPSE:NOVO B, is a key player in GLP-1 based therapies, with Wegovy at the center of its obesity drug portfolio. CVS Caremark's move...
Lilly has split its stock in the past.
United States Supreme Court upholds a $220 million Medicaid fraud verdict against Eli Lilly under the False Claims Act. Decision stems from a whistleblower case and concludes a 12 year legal dispute. Ruling is described as the first jury verdict against a pharmaceutical company under this statute. Eli Lilly, NYSE: LLY, now has a material legal setback sitting alongside a large market valuation, with the stock recently trading around $1,126.80. The company has very large multi year share...
The stock market hit fresh highs on Iran deal hopes. Nvidia, Tesla lead five trillion-dollar titans near buy points.
We just covered the Claude Stock Portfolio: Top 10 Stocks to Buy According to AI Chatbot. Eli Lilly and Company (NYSE:LLY) ranks #2 (see Claude Stock Portfolio: Top 5 Stocks to Buy According to AI Chatbot). Number of Hedge Funds: 137 Eli Lilly and Company (NYSE:LLY) is among the top stock picks of the Claude […]
Eli Lilly is near an all-time high in Friday's stock market after a strong first-quarter report. Shares are below a 1133.95 pivot.
Eli Lilly hits a record high after CVS expands coverage for Foundayo and Zepbound, boosting obesity drug access and raising the stakes in its rivalry with NVO.
CVS restores broader Zepbound coverage after price cuts, putting Wegovy and Zepbound on equal footing.
LLY's $4B vaccine push is boosting interest in healthcare ETFs like IHE with heavy exposure to the drugmaker.
Wall Street closed higher on Thursday, driven by tech and healthcare stocks.
Eli Lilly and Company (NYSE:LLY) was among the stocks Jim Cramer discussed on Mad Money, highlighting several companies with market caps over a trillion dollars. Cramer highlighted the company’s new cholesterol drug’s Phase 3 trial, as he commented: Finally, the 11th largest US company, holy cow…. smaller than Micron but still just over 1 trillion, […]
Eli Lilly's $1 trillion comeback is powered by the company's experimental next-generation obesity drug, Reta.
Eli Lilly and Company (NYSE:LLY) is one of the 12 Most Profitable Stocks to Invest In. On May 25, 2026, Eli Lilly and Company (NYSE:LLY) announced positive Phase 1b Heart-2 study results for Verve-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver and lower blood […]
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.4% in the afternoon session after CVS restored Zepbound as a co-preferred option and simultaneously added Lilly's new oral obesity pill Foundayo, making Eli Lilly's full obesity medication portfolio accessible to all three of America's largest pharmacy benefit managers for the first time.
The change could improve patient access and support future sales growth.
The move gives patients broader access to Lilly's obesity drugs and strengthens competition with Novo Nordisk.
Lilly will continue global launches despite MFN pricing uncertainty, Japan price cuts, and rising obesity-drug competition.
U.S. and Iranian negotiators agreed on a 60-day memorandum of understanding to extend the ceasefire, media reports suggested.
Megacap stocks dominate their sectors and their actions influence economies worldwide. The flip side though is that their sheer size means they have less room for explosive growth as scale works against them.
Eli Lilly and Company (NYSE:LLY) is included among the 10 Best Reddit Stocks to Buy According to Billionaires. On May 26, Reuters reported that Eli Lilly and Company (NYSE:LLY) plans to acquire three vaccine developers in deals worth up to $3.8 billion combined, marking a deeper push into infectious disease prevention. The US drugmaker said […]
The stock market rode a big rally in software stocks to fresh highs on Thursday despite another hot inflation report. The Nasdaq gained 0.9%. The Dow rose 25 points to post a slight gain and eke out a fresh record, too.
Eli Lilly shares are on pace to hit a new all-time closing high on news of increased insurance coverage for its blockbuster weight-loss drug Zepbound. Lilly shares were recently up 4.4% to $1,130.90. Pharmacy-benefit manager CVS Caremark decided to add back Lilly’s Zepbound weight-loss drug to its lists of preferred drugs.
CVS Health will reinstate coverage of Eli Lilly's weight-loss injectable Zepbound and begin coverage of the anti-obesity pill Foundayo.
CVS Health’s decision to expand formulary coverage for key GLP-1 therapies marks a boost for Eli Lilly's obesity drug business.
CVS Health’s Caremark will resume insurance coverage of Eli Lilly’s Zepbound and separately begin covering its Foundayo weight-loss pill.
Novo Nordisk lost its lead in the GLP-1 race, but Eli Lilly's valuation is a bit rich.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
